Physician profile
Daniel A Duprez
NPI 1609807825
$16,977.65
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,478 · 2020: $5,788 · 2021: $279 · 2024: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $875 · Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $875.01 |
| Food and Beverage | $557.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $10,777.70 | 2019-2020 | |
| Vifor Pharma, INC. | $3,874.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,432.03 | 2024 | |
| Medicure Pharma INC. | $614.58 | 2019 | |
| Medtronic, INC. | $279.17 | 2021 |
5 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Duprez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.